Epithelial-mesenchymal transition in carcinomas of the female genital tract

Histopathology

Volumn 62, Issue 1, 2013, Pages 31-43

  Stewart, Colin J R ^a   Mccluggage, W Glenn ^b  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Carcinoma; Cervix; EMT; Endometrium; Epithelial mesenchymal transition; Invasive front; MELF; Ovary

Indexed keywords

BETA CATENIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; INTERSTITIAL COLLAGENASE; K RAS PROTEIN; MACROPHAGE ELASTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN;

CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STEM CELL; CARCINOSARCOMA; CELL STRUCTURE; CYTOKINE RESPONSE; ENDOMETRIUM CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENOMICS; GYNECOLOGIC CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KERATINOCYTE; METHYLATION; OVARY CARCINOMA; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; UTERINE CERVIX CARCINOMA; VULVOVAGINAL CARCINOMA; WNT SIGNALING PATHWAY;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CARCINOSARCOMA; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871171526     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12057     Document Type: Review

References (83)

1. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007; 39; 305-318.
2. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002; 2; 442-454.
3. Hugo H, Ackland ML, Blick T et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 2007; 213; 374-383.
4. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005; 17; 548-558.
5. Iwatsuki M, Mimori K, Yokobori T et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010; 101; 293-299.
6. Bullock MD, Savan AE, Packham GK, Mirnezami AH. MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol. Cell 2012; 104; 3-12.
7. Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell. Mol. Life Sci. 2006; 63; 449-468.
8. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J. Pathol. 2003; 200; 429-447.
9. Talbot LJ, Bhattacharya SD, Kuo PC. E. Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial cells. Int. J. Biochem. Mol. Biol. 2012; 3; 117-136.
10. Tarin D. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 2005; 65; 5996-6000.
11. Garber K. Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. J. Natl Cancer Inst. 2008; 100; 232-233.
12. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006; 66; 8319-8326.
13. Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev. 2012; 31; 277-283.
14. Chui MH. Insights into cancer metastasis from a clinicopathologic perspective: epithelial-mesenchymal transition is not a necessary step. Int. J. Cancer 2012; [Epub ahead of print] doi:10.1002/ijc.27745.
15. McCluggage WG. A critical appraisal of the value of immunohistochemistry in diagnosis of uterine neoplasms. Adv. Anat. Pathol. 2004; 11; 162-171.
16. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009; 119; 1429-1437.
17. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition. A cancer researcher's conceptual friend and foe. Am. J. Pathol. 2009; 174; 1588-1593.
18. Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol. Cancer Res. 2010; 8; 629-642.
19. Prall P. Tumour budding in colorectal carcinoma. Histopathology 2007; 50(151-16); 2.
20. Le NH, Franken P, Fodde R. Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. Br. J. Cancer 2008; 98; 1886-1893.
21. Kahlert C, Lahes S, Radhakrishnan P et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin. Cancer Res. 2011; 17; 1-10.
22. Mak VCY, Siu MKY, Wong OGW, Chan KKL, Ngan HYS, Cheung ANY. Dysregulated stemness-related genes in gynaecological malignancies. Histol. Histopathol. 2012; 27; 1121-1130.
23. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 2012; [Epub ahead of print] doi:10.1007/s10555-012-9345-0.
24. Mani SA, Guo W, Liao M-J et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133; 704-715.
25. Alison MR, Lin W-R, Lim SML, Nicholson LJ. Cancer stem cells: in the line of fire. Cancer Treat. Rev. 2012; 38; 589-598.
26. Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J. Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. Exp. Biol. Med. 2011; 236; 537-545.
27. Zannoni GF, Prisco MG, Vellone VG, De Stefano I, Scambia G, Gallo D. Changes in the expression of oestrogen receptors and E-cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma. Histopathology 2011; 58; 265-275.
28. Pappa KI, Jacob-Hirsch J, Vlachos GD et al. Expression profiling of vulvar carcinoma: clues for deranged extracellular matrix remodeling and effects on multiple signalling pathways combined with discrete patient subsets. Transl. Oncol. 2011; 4; 301-313.
29. Orlichenko LS, Radisky DC. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin. Exp. Metastasis 2008; 25; 593-600.
30. Ellis PE, Cano SD, Fear M et al. Reduced E-cadherin expression correlates with disease progression in Paget's disease of the vulva but not Paget's disease of the breast. Mod. Pathol. 2008; 21; 1192-1199.
31. Ellis PE, MacLean AB, Crow JC, Wong Te Fong LF, Rolfe KJ, Perrett CW. Expression of cyclin D1 and retinoblastoma protein in Paget's disease of the vulva and breast: an immunohistochemical study. Histopathology 2009; 55; 709-715.
32. Knopp S, Bjorge T, Nesland JM, Trope C, Holm R. Cyclins D1, D3, E, and A in vulvar carcinoma patients. Gynecol. Oncol. 2005; 97; 733-799.
33. Rolfe KJ, Crow JC, Benjamin E, Reid WM, Maclean AB, Perrett CW. Cyclin D1 and retinoblastoma protein in vulvar cancer and adjacent lesions. Int. J. Gynecol. Cancer 2001; 11; 381-386.
34. Hantschmann P, Lampe B, Beysiegel S, Kurzl R. Tumor proliferation in squamous cell carcinoma of the vulva. Int. J. Gynecol. Pathol. 2000; 19; 361-368.
35. Hendricks JB, Wilkinson EJ, Kubilis P, Drew P, Blaydes SM, Munakata S. Ki-67 expression in vulvar carcinoma. Int. J. Gynecol. Pathol. 1994; 13; 205-210.
36. Lee M-Y, Shen M-R. Epithelial-mesenchymal transition in cervical carcinoma. Am. J. Transl. Res. 2012; 4; 1-13.
37. Hellner K, Mar J, Fang F, Quackenbush J, Munger K. HPV16 E7 oncogene expression in normal human epithelial cells causes molecular changes indicative of an epithelial to mesenchymal transition. Virology 2009; 391; 57-63.
38. Cheng Y-M, Chou C-Y, Hsu Y-C, Chen M-J, Wing L-YC. The role of human papillomavirus type 16 E6/E7 oncoproteins in cervical epithelial-mesenchymal transition and carcinogenesis. Oncol. Lett. 2012; 3; 667-671.
39. Lee M-Y, Chou C-Y, Tang M-J, Shen M-R. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression and Snail up-regulation. Clin. Cancer Res. 2008; 14; 4743-4750.
40. Yi JY, Hur KC, Lee E, Jin YJ, Arteaga CL, Son YS. TGFbeta1-mediated epithelial to mesenchymal transition is accompanied by invasion in the SiHa cell line. Eur. J. Cell Biol. 2002; 81; 457-468.
41. Chung MT, Lai HC, Sytwu HK et al. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol. Oncol. 2009; 112; 646-653.
42. Chung MT, Sytwu HK, Yan MD et al. Promoter methylation of SFRPs gene family in cervical cancer. Gynecol. Oncol. 2009; 112; 301-306.
43. Lin YW, Chung MT, Lai HC et al. Methylation analysis of SFRP genes family in cervical adenocarcinoma. J. Cancer Res. Clin. Oncol. 2009; 135; 1665-1674.
44. Hagemann T, Bozanovic T, Hooper S et al. Molecular profiling of cervical cancer progression. Br. J. Cancer 2007; 96; 321-328.
45. Stewart CJR, Crook ML, Little L, Louwen K. Correlation between invasive pattern and immunophenotypic alterations in endocervical adenocarcinoma. Histopathology 2011; 58; 720-728.
46. Stewart CJR, Little L. Diagnostic value and implications of vimentin expression in normal, reactive and neoplastic endocervical epithelium. Pathology 2010; 42; 217-223.
47. Stewart CJR, Crook M, Loi S. Fascin expression in endocervical neoplasia: correlation with tumour morphology and growth pattern. J. Clin. Pathol. 2012; 65; 213-217.
48. Koay MHE, Crook M, Stewart CJR. Cyclin D1, E-cadherin and beta-catenin in FIGO stage IA cervical squamous carcinoma: diagnostic value and evidence for epithelial-mesenchymal transition. Histopathology 2012; [Epub ahead of print] doi 10.1111/j.1365-2559.2012.04326.x.
49. Llobet D, Pallares J, Yeramian A et al. Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutical view points. J. Clin. Pathol. 2009; 62; 777-785.
50. Colas E, Pedrola N, Deva L et al. The EMT signalling pathways in endometrial carcinoma. Clin. Transl. Oncol. 2012; 14; 715-720.
51. Montserrat N, Moros A, Llobet D et al. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum. Pathol. 2012; 43; 632-643.
52. Kyo S, Sakaguchi J, Ohno S et al. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum. Pathol. 2006; 37; 431-438.
53. Koyuncuoglu M, Okyay E, Saatli B, Olgan S, Akin M, Saygili U. Tumor budding and E-cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer? Gynecol. Oncol. 2012; 125; 208-213.
54. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinomas: a study of their frequency, associated diagnostic problems, and prognostic significance. Int. J. Gynecol. Pathol. 2003; 22; 324-333.
55. Stewart CJR, Brennan BA, Leung YC, Little L. MELF pattern invasion in endometrial carcinoma: association with low-grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 2009; 41; 454-459.
56. Stewart CJR, Little L. Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 2009; 55; 91-101.
57. Stewart CJR, Crook ML, Leung YC, Platten M. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod. Pathol. 2009; 22; 725-733.
58. Stewart CJ, Crook ML, Lacey J, Louwen K. Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium. Int. J. Gynecol. Pathol. 2011; 30; 484-491.
59. Stewart CJR, Crook ML, Manso L. Fascin expression in low-grade uterine endometrioid adenocarcinoma; correlation with MELF type alteration at the deep invasive margin. Histopathology 2011; 59; 73-80.
60. Stewart CJ, Crook ML. Galectin-3 expression in uterine endometrioid adenocarcinoma: comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion. Int. J. Gynecol. Pathol. 2010; 29; 555-561.
61. Stewart CJ, Crook ML. CD147 (EMMPRIN) and matrix metalloproteinase-2 expression in uterine endometrioid adenocarcinoma. Pathol. Res. Pract. 2011; 207; 30-36.
62. Stewart CJR, Crook ML, Doherty DA. Micro-anatomical variation in cellular proliferation in endometrial adenocarcinoma, and inverse correlation between Ki67 and cytokeratin 7 expression. Histopathology 2010; 57; 46-54.
63. Shih I-M, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int. J. Gynecol. Pathol. 2001; 20; 31-47.
64. Kokkinos MI, Murthi O, Wafai R, Thompson EW, Newgreen DF. Cadherins in the human placenta - epithelial-mesenchymal transition (EMT) and placental development. Placenta 2010; 31; 747-755.
65. INK4A and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res. 2003; 63; 1737-1742.
66. INK4A and is a region of low proliferation. Am. J. Pathol. 2001; 159; 1613-1617.
67. Palmqvist R, Sellberg P, Oberg A et al. Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br. J. Cancer 1999; 79; 577-581.
68. Davidson B, Trope CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Front. Oncol. 2012; 2; 33.
69. Vergara D, Merlot B, Lucot J-P et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010; 291; 59-66.
70. Tseng CH, Muaary KD, Jou MF, Hsu SM, Cheng HJ, Huang PH. Sema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer. PLoS ONE 2011; 6; 319-396.
71. Cheng J-C, Auersperg N, Leung PCK. EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS ONE 2012; 7; e34071.
72. Rosano L, Spinella F, Di Castro V et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 2005; 65; 11649-11657.
73. Yoshida S, Furukawa N, Haruta S et al. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma. A review. Int. J. Gynecol. Cancer 2009; 19; 992-997.
74. Latifi A, Abubaker K, Castrechini N et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell. Biochem. 2011; 112; 2850-2864.
75. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl Acad. Sci. USA 2012; 109; 3921-3926.
76. Silva EG. The stromal origin of some epithelial ovarian neoplasms. 'Fere ex nihilo'. Int. J. Gynecol. Cancer 2012; 22; 906-907.
77. Lopez-Garcia MA, Palacios J. Pathologic and molecular features of uterine carcinosarcomas. Semin. Diagn. Pathol. 2010; 27; 274-286.
78. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J. Clin. Pathol. 2002; 55; 321-325.
79. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int. J. Gynecol. Cancer 2002; 12; 687-690.
80. Chiyoda T, Tsuda H, Tanaka H et al. Expression profiles of carcinosarcoma of the uterine corpus - are these similar to carcinoma or sarcoma? Genes Chromosom. Cancer 2012; 51; 229-239.
81. Castilla MA, Moreno-Bueno G, Romero-Perez L et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J. Pathol. 2011; 223; 72-80.
82. Saegusa M, Hashimura M, Kuwata T, Okayasu I. Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am. J. Pathol. 2009; 174; 2107-2115.
83. Brabletz T. To differentiate or not - routes towards metastasis. Nat. Rev. Cancer 2012; 12; 425-436.